Related Experiment Videos
Current status of pyrazoloacridine as an anticancer agent
1Mayo Clinic and Foundation, Division of Medical Oncology, Rochester, MN 55905, USA. adjei.alex@mayo.edu
Investigational New Drugs
|November 11, 1999
Summary
Pyrazoloacridine (PZA) is a novel anticancer agent that inhibits DNA topoisomerases. It shows broad antitumor activity, including against resistant cells, but lacks efficacy in gastrointestinal cancers and prostate cancer.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Pyrazoloacridine (PZA) represents a new class of anticancer agents.
- PZA is a rationally synthesized acridine derivative undergoing clinical trials.
Purpose of the Study:
- To evaluate the anticancer potential of Pyrazoloacridine (PZA).
- To investigate the mechanism of action and unique properties of PZA.
Main Methods:
- Preclinical studies in vivo to assess antitumor activity.
- Phase I and II clinical trials in adult and pediatric patients.
- Evaluation of PZA activity against drug-resistant cell lines and hypoxic cells.
Main Results:
- PZA demonstrates broad-spectrum antitumor activity in preclinical models.
- It exhibits selectivity for solid tumors and activity against hypoxic and noncycling cells.
- PZA retains activity against cells resistant to P-glycoprotein and MRP, but shows no significant efficacy in gastrointestinal malignancies and prostate cancer.
Conclusions:
- PZA possesses a unique dual mechanism of action, inhibiting DNA topoisomerase I and II.
- Its distinct properties warrant further investigation, including combination studies with other antineoplastic agents.
- Ongoing trials will define PZA's role in cancer treatment armamentarium.